Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study

BACKGROUND: The first‐line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibody (mAb) is the more effective addition to a chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yi‐Hsin, Chen, Kuo‐Hsing, Shao, Yu‐Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417087/
https://www.ncbi.nlm.nih.gov/pubmed/37325970
http://dx.doi.org/10.1002/cam4.6196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417087/
https://www.ncbi.nlm.nih.gov/pubmed/37325970
http://dx.doi.org/10.1002/cam4.6196

Ejemplares similares